SWOG clinical trial number
SWOG-8692 (INT-0075)

Therapy In Premenopausal Women with Advanced, ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs. the LH-RH Analog, Zoladex

Closed
Phase
Accrual
77%
Published
Abbreviated Title
Therapy In Premenopausal Women with Advanced, ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs. the LH-RH Analog, Zoladex
Activated
08/01/1987
Closed
07/15/1995

Research committees

Breast Cancer

Publication Information Expand/Collapse

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

1998

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study.

CW Taylor;S Green;WS Dalton;S Martino;D Rector;JN Ingle;NJ Robert;GT Budd;JC Paradelo;RB Natale;JD Bearden;JA Mailliard;CK Osborne Journal of Clinical Oncology 16(3):994-999

1996

Phase 3, randomized, multi-center comparison of zoladex versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer.

CW Taylor;S Green;WS Dalton;S Martino;JN Ingle;NJ Robert;CK Osborne Proc Sixth International Congress on Anti-Cancer Treatment :(#120)

1995

A multi-center randomized trial of zoladex versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic brease cancer.

CW Taylor;S Green;WS Dalton;S Martino;JN Ingle;NJ Robert;DJ Rector;CK Osborne Breast Cancer Research and Treatment 37:37(#19)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase